October 16, 2025 Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient Meeting Enrollment underway for the global, multicenter, double-blind Phase 2b trial assessing efficacy and safety of ninerafaxstat in patients with […] The post Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafax
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules